Company Overview of Alios BioPharma, Inc.
Alios BioPharma, Inc. operates as a biotechnology company that develops novel antiviral therapies for the treatment of respiratory diseases in patients worldwide. The company develops AL-8176, an anti-respiratory syncytial virus (RSV) nucleoside analog for the treatment of RSV; AL-335, a potent uridine based nucleotide analog; and AL-516, a potent guanosine based nucleotide analog. It offers its therapeutics for viral infections, including influenza, rhinovirus, coronavirus, and hepatitis C. The company was incorporated in 2006 and is based in South San Francisco, California. As of November 7, 2014, Alios BioPharma, Inc. operates as a subsidiary of Janssen Pharmaceuticals, Inc.
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2006
Key Executives for Alios BioPharma, Inc.
Founder, Chief Executive Officer, President and Director
Founder and Chief Scientific Officer
Founder and Chief Business Officer
Senior Director of Operations and Project Management
Vice President of Drug Discovery
Compensation as of Fiscal Year 2015.
Alios BioPharma, Inc. Key Developments
JAlios Biopharma Inc. Initiates Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics
Aug 3 15
Alios Biopharma Inc. has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102) on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir and odalasvir, a HCV NS5A inhibitor, on the pharmacokinetics of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets which include odalasvir (ACH-3102), ACH-3422, and sovaprevir.
Alios Biopharma, Inc. to Present Preclinical Data on its Anti HCV Nucleotides Al 335 and Al 516
Nov 7 14
Alios BioPharma, Inc. announced the upcoming presentation of preclinical data from two of its anti-hepatitis C virus (HCV) nucleotide analogs at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) beginning in Boston. Data from two novel compounds AL-335, a potent uridine based nucleotide analog and AL-516, a potent guanosine based nucleotide analog will be presented in two poster sessions on November 11. AL-335 is a monophosphate prodrug of a uridine-based nucleotide analog and has been identified as a potent inhibitor of NS5B-directed HCV RNA replication. Results presented previously have shown that AL-335 demonstrates potent inhibition of HCV in the cell-based replicon assay across genotypes. In this most recent study, AL-335 was examined in pairwise combinations with multiple classes of compounds either approved for the treatment of chronic hepatitis C (CHC) or currently in clinical development. The classes of compounds tested included NS3/4A protease inhibitors, NS5A inhibitors, nucleoside/tide and non-nucleoside polymerase inhibitors, cyclophilin A inhibitors, type I and type III interferons (IFNs) and ribavirin (RBV). All of the combinations were either additive or synergistic in vitro, and no antagonistic effects were observed. The combination of AL-335 with the NS3/4A inhibitor simeprevir (Olysio) demonstrated a high level of synergy. AL-516, the guanosine-based nucleotide analog, was evaluated using the HCV replicon system encoding NS5B sequences from multiple genotypes and resistant variants and was profiled for its effects on cell viability and mitochondrial toxicity. The nucleoside 5'-triphosphate (AL-516 NTP) was tested against the HCV polymerase NS5B and for selectivity against human DNA and RNA polymerases. In the stable genotype (GT) 1b replicon assay, AL-516 exhibited potent antiviral activity with an EC(sub)50(/sub) of 7 nM. In transient chimeric GT-1b replicons with NS5B regions derived from GT 1-4, AL-516 demonstrated pan-genotypic activity with EC(sub)50(/sub) values (10 nM. AL-516 retained activity versus replicon mutants resistant to other nucleoside inhibitors. AL-516 exhibited an excellent selectivity profile with no inhibition of mitochondrial protein synthesis (IC(sub) 50(/sub))100 ÎM).
Alios BioPharma, Inc. Reports Positive Results of its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Challenge Study in Adults Infected With Respiratory Syncytial Virus
Jul 23 14
Alios BioPharma, Inc. announced positive results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus (RSV). AL-8176 achieved its primary and secondary endpoints of reduction in viral load (p < 0.0002) and improvement in symptom scores (p < 0.02) as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. The Alios study enrolled 62 healthy adults who received one of three dose regimens of AL-8176 or placebo over 5 days: 375 mg orally administered twice daily or 750 mg given as a single loading dose followed by twice daily maintenance doses of 150 mg or 500 mg. Administration of AL-8176 began approximately 12 hours after confirmation of RSV infection as determined by presence of RSV RNA in nasopharyngeal washes. In successfully infected subjects, marked immediate reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo where subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at day 3.5 following start of dosing. At discharge (day 12), all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable on follow-up on days 16 and 28. This is in contrast to placebo treated subjects who had a mean RSV RNA of 0.52 log(10) plaque forming unit equivalents (PFUe) /mL on the day of discharge. The viral load reduction in infected subjects across all dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 30, 2014